Background. A household contact substudy was performed as part of a prospective, cohort
pertussis vaccine efficacy trial in Germany. Design. Infants received four doses of either the …

Healthy 4–6 y old children from Italy and Sweden immunized with DTPa and inactivated or
oral polio vaccines at 3, 5 and 11–12 months of age, received 1 dose of combined DTPa-IPV …

Background Increasing evidence shows that protection induced by acellular pertussis
vaccines is short-lived, requiring repeated booster vaccination to control pertussis disease …

The recent increase of pertussis in young adults in Japan is hypothesized to be due in part
to waning protection from the acellular pertussis vaccine. While a booster immunization may …

OBJECTIVE: The safety of a booster dose of a reduced-antigen-content tetanus–diphtheria–
acellular pertussis (Tdap) vaccine was evaluated in adolescents previously vaccinated with …

Background. The high reactogenicity of whole cell pertussis vaccines discourages their use
in children. While acellular pertussis vaccines are less reactogenic, their use in diphtheria …

Safety, immunogenicity and lot consistency of five-component pertussis combination vaccine
(CPDT-IPV/PRP-T) in infants were compared to that of whole cell pertussis combination …

The objective of this open study was to monitor the long-term effectiveness of the Lederle-
Takeda diphtheria and tetanus toxoids and acellular pertussis antigen (s)(DTaP) vaccine …

Despite high vaccination coverage worldwide, pertussis has re-emerged in many countries.
This randomized, controlled, observer-blind phase I study and extension study in Belgium …

Reduced-antigen, combined diphtheria, tetanus and three-component acellular pertussis
vaccine (Tdap; Boostrix®) is indicated for booster vaccination against diphtheria, tetanus …